Empower early detection of metabolic-associated steatotic
liver disease (MASLD) with ACUSON Sequoia, offering
comprehensive liver assessments to enhance patient care and
reduce invasive procedures.
Early detection plays a key role in managing and potentially reversing
MASLD,1 which often progresses without noticeable symptoms. This can
lead to severe complications such as liver transplants and hepatocellular
carcinoma.2 Increasing access to noninvasive, cost-effective screenings
is essential in addressing this growing health concern.